Hamburg, December 22 – The Hamburg Regional Court has accepted an indictment against a local pharmaceutical company, Alanta Health Group, on suspicion of bribery and commercial billing fraud. The charges, initially filed by the public prosecutor’s office this summer, allege a scheme involving cancer medications.
Alanta Health Group Under Scrutiny
Alanta Health Group, a Hamburg-based company, specializes in the production of cancer medications. In addition to its manufacturing operations, the group also manages numerous medical care centers and a district clinic located in the Mümmelmannsberg area of Hamburg.
Allegations of Bribery and Fraud
Prosecutors accuse company officials of bribing doctors within the Alanta Group’s own network to prescribe expensive cancer drugs produced by the company. This practice, according to the indictment, led to significant financial losses for statutory health insurance companies.
75 Million Euros Allegedly Defrauded from Health Insurers
While the public prosecutor’s office emphasizes that there was no improper medical treatment of patients, the alleged scheme resulted in a substantial financial impact. Health insurance companies were reportedly defrauded of a total of 75 million euros due to the fraudulent billing practices.
Company Denies Allegations
Alanta Health Group has vehemently denied the accusations. A company spokesperson stated that such billing fraud did not occur within their system. The company has welcomed the court’s decision to proceed with the case, expressing confidence that the allegations will be clarified and ultimately dismissed during the legal proceedings.
The exact date for the start of the main trial has not yet been set by the Higher Regional Court.
Background: Indictment Follows Extensive Investigation
The indictment by the Hamburg public prosecutor’s office targets six individuals connected to the company, following an extensive investigation into the alleged millions-worth fraud involving cancer medications. This development was highlighted in the Hamburg Journal television program on NDR Fernsehen on December 22, 2025, at 7:30 PM.
The case underscores ongoing efforts to combat healthcare fraud and ensure fair practices within the pharmaceutical industry. The outcome of the trial is anticipated to have significant implications for the company and potentially for regulatory oversight within the German healthcare system.
Source: https://www.ndr.de/nachrichten/hamburg/krebsmedikamente-anklage-wegen-bestechung-und-abrechnungsbetrug,krebsmittel-100.html
